Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711270 | 0.87 | PIK3CA (0.61) | PTGS2BCHEACHEPIK3CAPIK3CB | |
| SCHEMBL15295907 | 0.78 | HCAR3 (0.49) | HCAR2PIK3CAGAAMAPK1KDM4E | |
| SCHEMBL992895 | 0.77 | PTGS2 (0.52) | PTGS2ATMDAPK3JAK2PAK4 | |
| SCHEMBL14842053 | 0.77 | NOS2 (0.58) | PTGS2ATMDAPK3JAK2PAK4 | |
| SCHEMBL16039107 | 0.77 | LMNA (0.62) | PTGS2ATMDAPK3JAK2PAK4 | |
| SCHEMBL7284762 | 0.77 | SMN1; SMN2 (0.55) | PTGS2PIK3CBDAPK3JAK2PAK4 | |
| SCHEMBL9884921 | 0.76 | DAPK3 (0.56) | PTGS2DAPK3JAK2PAK4ABL1 | |
| SCHEMBL7653540 | 0.76 | ALDH1A1 (0.53) | PTGS2L3MBTL1ALDH1A1HPGDMEN1 | |
| SCHEMBL453455 | 0.76 | CTRC (0.57) | HCAR2PTGS2ATMCLK4LMNA | |
| SCHEMBL7277226 | 0.76 | MEN1 (0.47) | PTGS2BCHEACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4029785-A | BACTERICIDES, FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1977-06-14 | — | — | US | claimed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| EP-2410857-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | HCAR2 113/4885PTGS2 450/4885ATM 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.